Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s MOH Releases Criteria For Illegal Food Additives

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health has published a list of the first batch of banned food additives. The blacklist aims to provide leads for nine relevant authorities that jointly started special investigations on food additives on Dec. 10. MOH states the in-principle definition of a substance being an illegal additive as follows: (1) not belonging to conventional raw food materials; (2) not approved as a new food resource; (3) not under MOH's recognized food and drug substances or common food materials; (4) not included in China's catalog of food additives and nutritional fortifiers; and (5) not included in the list of substances whose use is allowed by other laws or regulations. Items that violate any of the criteria will be ruled as illegal food additives. (Click here for more - Chinese Language)

You may also be interested in...



Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel